EndoBarrier Therapy Data to be Presented at American Diabetes Association Annual Meeting

LEXINGTON, Massachusetts and SYDNEY, Australia – 9 June 2016 – GI Dynamics, Inc. (ASX:GID), a medical device company that has developed an innovative endoscopically delivered treatment for type 2 diabetes and obesity, announced today that results from three clinical studies involving EndoBarrier Therapy will be presented at the American Diabetes Association’s (ADA) 76th Scientific Sessions in New Orleans, Louisiana, June 10–14, 2016.

Final data from the ENDO Trial, GI Dynamics’s U.S. pivotal clinical trial of EndoBarrier Therapy, will be presented during a poster session on Sunday, June 12. Previously, preliminary results and the topline results of the ENDO Trial data have been made public. The poster, presented by the ENDO Trial’s coprincipal investigator, Lee Kaplan, M.D., Ph.D., will include primary efficacy and safety data as well as secondary efficacy outcomes.

The dates, times and session numbers for all presentations pertaining to EndoBarrier Therapy are as follows:

American Diabetes Association 76th Scientific Sessions

June 10–14  •  Ernest N. Morial Convention Center in New Orleans, Louisiana


Saturday, June 11

12:30 to 1:30 p.m.


Benefits Galore of Bariatric Surgery and Bypass Liners—Human Trials  Katharina Laubner, Universitätsklinikum Freiburg, Germany 


Sunday, June 12

12 to 2 p.m.

Bypass Liner Reduces Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Patients with Type 2 Diabetes (T2DM)                                                              Katharina Laubner, Universitätsklinikum Freiburg, Germany


Sunday, June 12

12 to 2 p.m.

EndoBarrier Therapy is Associated with Glycemic Improvement, Weight Loss and Safety Issues in Patients with Obesity and Type 2 Diabetes on Oral Antihyperglycemic Agents                                                                                                  Lee Kaplan et. al., Massachusetts General Hospital, Boston, Massachusetts 


Sunday, June 12

2:45 to 3 p.m.

The Effect of 1-Year’s Endoscopic Proximal Intestinal Exclusion Using EndoBarrier on 10-Year Cardiovascular Risk in Type 2 Diabetes                     Robert E. Ryder et al., Sandwell and West Birmingham Hospitals NHS Trust,  UK 

“We are very excited to release the final results of our ENDO Trial at the American Diabetes Association meeting and to have the opportunity to discuss our data with diabetes experts from around the world,” said Scott Schorer, president and CEO of GI Dynamics, Inc.

“We’re also pleased to have additional aspects of EndoBarrier Therapy – namely, its effect on non-alcoholic fatty liver disease and 10-year cardiovascular risk – presented at ADA, and we’re proud to be included in a moderated discussion on the benefits of bariatric surgery and bypass liners in treating obese type 2 diabetes. We look forward to the presentations of Drs. Laubner, Kaplan and Ryder and appreciate their and their colleagues’ contributions to the body of work supporting EndoBarrier Therapy.”

The company will release further details regarding these presentations following the ADA meeting.